Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Recall test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    194 result(s) found for: Recall test. Displaying page 9 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2015-002478-19 Sponsor Protocol Number: SHP616-300 Start Date*: 2016-06-28
    Sponsor Name:Shire ViroPharma, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Este...
    Medical condition: hereditary angioedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005912-23 Sponsor Protocol Number: A3191219 Start Date*: 2008-07-10
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX®) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE...
    Medical condition: Relief of signs and symptoms of acute gouty arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018634 Gouty arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005210-22 Sponsor Protocol Number: BOOG-2017-02 Start Date*: 2018-04-25
    Sponsor Name:BOOG Study Center
    Full Title: Explorative trial to identify the impact of denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal patients with HER2 negative breast cancer.
    Medical condition: Mamma carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002556-32 Sponsor Protocol Number: ANTIC:6672 Start Date*: 2013-09-05
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Antibiotic treatment for intermittent bladder catheterisation: A randomised controlled trial of once daily prophylaxis (The AnTIC study)
    Medical condition: Recurrent urinary tract infection in people who use intermittent bladder catheterisation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10064736 Antibiotic prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000870-20 Sponsor Protocol Number: IMU-AD-001 Start Date*: 2015-05-27
    Sponsor Name:Immungenetics AG
    Full Title: An open-label, multicenter, controlled pharmaco-dynamic clinical trial to explore the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with early-to-mild dementia due to Alzheimer...
    Medical condition: Newly diagnosed early-to-mild dementia due to Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004042-14 Sponsor Protocol Number: 16-OBE2109-015 Start Date*: 2018-04-23
    Sponsor Name:ObsEva SA
    Full Title: An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis.
    Medical condition: Uterine adenomyosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10058953 Adenomyosis uteri LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001695-26 Sponsor Protocol Number: FARM1275JK Start Date*: 2018-09-12
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Monitoring the effectiveness and safety of biological drugs for treatment of psoriasis through evaluation of clinical and biological markers
    Medical condition: Moderate to severe psoriasis and joint disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003766-27 Sponsor Protocol Number: 848015011 Start Date*: 2018-07-18
    Sponsor Name:VU University Medical Centre
    Full Title: The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder: a double-blind, randomized, placebo-controlled trial in general practice
    Medical condition: Insonnia disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10078083 Insomnia disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005090-53 Sponsor Protocol Number: BAY98-7196/15832 Start Date*: 2014-09-02
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    18.1 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed) DK (Completed) AT (Completed) BE (Completed) NL (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002326-27 Sponsor Protocol Number: COG0201 Start Date*: 2022-09-14
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001599-12 Sponsor Protocol Number: ASC-Man-P016 Start Date*: 2019-10-21
    Sponsor Name:Ascelia Pharma AB
    Full Title: A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment
    Medical condition: MRI in terms of visualization of detected focal liver lesions in patients with known or Suspected focal liver lesions and severe renal impairment
    Disease: Version SOC Term Classification Code Term Level
    22.1 10022891 - Investigations 10028049 MRI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001572-19 Sponsor Protocol Number: 14122A Start Date*: 2011-12-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD)
    Medical condition: -Cognitive dysfunction -Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10057668 Cognitive disorder PT
    14.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Completed) LV (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012935-13 Sponsor Protocol Number: D9120C00019 Start Date*: 2009-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in ...
    Medical condition: Gastroesophageal Reflux Disease (GERD) is the intended indication.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10017924 Gastroesophageal reflux LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005329-11 Sponsor Protocol Number: FX006-2014-008 Start Date*: 2015-02-26
    Sponsor Name:Flexion Therapeutics
    Full Title: A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients with Osteoarthritis of the Knee
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000473-68 Sponsor Protocol Number: KF6005/08 Start Date*: 2013-08-21
    Sponsor Name:Grünenthal GmbH
    Full Title: Efficacy, safety and tolerability of multiple doses of oral cebranopadol in subjects with moderate to severe chronic pain due to diabetic peripheral neuropathy
    Medical condition: Moderate to severe chronic pain due to diabetic peripheral neuropathy (DPN) requiring analgesia in subjects with well-controlled and stable type 1 or type 2 diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10012680 Diabetic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) NL (Completed) BE (Completed) ES (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000229-19 Sponsor Protocol Number: 15905A Start Date*: 2014-09-19
    Sponsor Name:H. Lundbeck A/S
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major de...
    Medical condition: Major Depressive Disorder and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003772-39 Sponsor Protocol Number: DEMAND-pilot Start Date*: 2019-12-13
    Sponsor Name:Umeå University
    Full Title: Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impair...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-002885-38 Sponsor Protocol Number: HGT-HIT-094 Start Date*: 2013-10-22
    Sponsor Name:Shire HGT Inc
    Full Title: A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and...
    Medical condition: Long-term treatment of Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003796-17 Sponsor Protocol Number: CST103/CST139-CLIN-010 Start Date*: 2020-10-22
    Sponsor Name:CuraSen Therapeutics, Inc.
    Full Title: An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139
    Medical condition: Patients with Mild Cognitive Impairment or Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 06:46:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA